What type of study is this?

September 5, 2025Open Access

Supplementary Figure 6 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

Prognostic stratification reveals insights into patient outcomes in metastatic urothelial cancer.
ctDNA and tissue assessments demonstrate a strong correlation with ECOG performance status, aiding treatment decisions.
Assessment involves ctDNA analysis alongside tissue examination of ERBB2 and HER2 alterations.
Highlights the need for personalized treatment approaches based on biomarker evaluations in metastatic urothelial cancer.

Abstract

Supplementary Figure 6. Prognostic stratification of metastatic urothelial cancer (mUC) by ctDNA and tissue ERBB2/HER2 status and Eastern Cooperative Oncology Group (ECOG) performance status.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Vandekerkhove et al. (Tue,) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02af8 https://doi.org/https://doi.org/10.1158/1078-0432.30029645

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper